Ken Natsuga, Daisuke Tsuruta, Shota Takashima, Chiharu Tateishi, Masaaki Takatoku, Brittani Agostini, Sarrah Mailliard, Nicholas J. Reitze, Rebecca T. Beacham, Alexia M. Cardiges, Michael J. Johnston, Ramakrishna Edukulla, Suma M. Krishnan
{"title":"局部基因疗法Beremagene Geperpavec-svdt （B-VEC）在日本营养不良大疱性表皮松解症患者的疗效和安全性的开放标签研究","authors":"Ken Natsuga, Daisuke Tsuruta, Shota Takashima, Chiharu Tateishi, Masaaki Takatoku, Brittani Agostini, Sarrah Mailliard, Nicholas J. Reitze, Rebecca T. Beacham, Alexia M. Cardiges, Michael J. Johnston, Ramakrishna Edukulla, Suma M. Krishnan","doi":"10.1111/1346-8138.17863","DOIUrl":null,"url":null,"abstract":"<p>Dystrophic epidermolysis bullosa (DEB) patients have pathogenic variants in <i>COL7A1</i>, leading to skin fragility, blistering, and scarring. Beremagene geperpavec-svdt (B-VEC) is a replication-defective herpes simplex virus type 1 (HSV-1)-based gene therapy vector administered topically to deliver functional <i>COL7A1</i> to DEB wounds. In a United States (US) Phase 3 study, B-VEC significantly improved wound healing at 3 and 6 months compared to placebo, and in a US open-label extension (OLE) study, weekly B-VEC administration was well tolerated for up to 112 weeks. The present study was conducted to confirm the efficacy and safety of B-VEC in a cohort of Japanese DEB patients receiving weekly B-VEC treatment (4.0 × 10<sup>9</sup> plaque forming units (PFU)/mL) for 52 weeks. Wound healing assessments were conducted on a Primary Wound at visits corresponding to Month 3 (the secondary efficacy endpoint), Month 6 (the primary efficacy endpoint), and Months 9 and 12 (exploratory durability endpoints). Patient-reported outcome (PRO) measures were employed as exploratory analyses of efficacy. Safety was assessed by adverse events (AEs) and clinical laboratory tests. Five subjects enrolled in the study; one discontinued due to challenges with following wound dressing disposal guidelines. The study met its primary and secondary efficacy endpoints with 100% of Primary Wounds demonstrating complete closure at Months 6 and 3, respectively; durable complete closure was observed in 3/4 (75%) of wounds at Months 9 and 12. PROs indicated decreased pain, improvement in skin-specific quality of life, and moderate to high treatment satisfaction. Four subjects reported ten AEs; all were assessed as mild or moderate in severity and unrelated to treatment by Investigators. None were serious, severe, or led to treatment/study discontinuation. The results of the Japan OLE study are in agreement with the US Phase 3 and OLE studies, demonstrating the efficacy and safety of B-VEC in Japanese patients with DEB.</p><p><b>Trial Registration:</b> Japan Registry of Clinical Trials: jRCT2053230075</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"1494-1502"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17863","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Study of Japanese Subjects With Dystrophic Epidermolysis Bullosa\",\"authors\":\"Ken Natsuga, Daisuke Tsuruta, Shota Takashima, Chiharu Tateishi, Masaaki Takatoku, Brittani Agostini, Sarrah Mailliard, Nicholas J. Reitze, Rebecca T. Beacham, Alexia M. Cardiges, Michael J. Johnston, Ramakrishna Edukulla, Suma M. Krishnan\",\"doi\":\"10.1111/1346-8138.17863\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Dystrophic epidermolysis bullosa (DEB) patients have pathogenic variants in <i>COL7A1</i>, leading to skin fragility, blistering, and scarring. Beremagene geperpavec-svdt (B-VEC) is a replication-defective herpes simplex virus type 1 (HSV-1)-based gene therapy vector administered topically to deliver functional <i>COL7A1</i> to DEB wounds. In a United States (US) Phase 3 study, B-VEC significantly improved wound healing at 3 and 6 months compared to placebo, and in a US open-label extension (OLE) study, weekly B-VEC administration was well tolerated for up to 112 weeks. The present study was conducted to confirm the efficacy and safety of B-VEC in a cohort of Japanese DEB patients receiving weekly B-VEC treatment (4.0 × 10<sup>9</sup> plaque forming units (PFU)/mL) for 52 weeks. Wound healing assessments were conducted on a Primary Wound at visits corresponding to Month 3 (the secondary efficacy endpoint), Month 6 (the primary efficacy endpoint), and Months 9 and 12 (exploratory durability endpoints). Patient-reported outcome (PRO) measures were employed as exploratory analyses of efficacy. Safety was assessed by adverse events (AEs) and clinical laboratory tests. Five subjects enrolled in the study; one discontinued due to challenges with following wound dressing disposal guidelines. The study met its primary and secondary efficacy endpoints with 100% of Primary Wounds demonstrating complete closure at Months 6 and 3, respectively; durable complete closure was observed in 3/4 (75%) of wounds at Months 9 and 12. PROs indicated decreased pain, improvement in skin-specific quality of life, and moderate to high treatment satisfaction. Four subjects reported ten AEs; all were assessed as mild or moderate in severity and unrelated to treatment by Investigators. None were serious, severe, or led to treatment/study discontinuation. The results of the Japan OLE study are in agreement with the US Phase 3 and OLE studies, demonstrating the efficacy and safety of B-VEC in Japanese patients with DEB.</p><p><b>Trial Registration:</b> Japan Registry of Clinical Trials: jRCT2053230075</p>\",\"PeriodicalId\":54848,\"journal\":{\"name\":\"Journal of Dermatology\",\"volume\":\"52 10\",\"pages\":\"1494-1502\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17863\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17863\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17863","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Study of Japanese Subjects With Dystrophic Epidermolysis Bullosa
Dystrophic epidermolysis bullosa (DEB) patients have pathogenic variants in COL7A1, leading to skin fragility, blistering, and scarring. Beremagene geperpavec-svdt (B-VEC) is a replication-defective herpes simplex virus type 1 (HSV-1)-based gene therapy vector administered topically to deliver functional COL7A1 to DEB wounds. In a United States (US) Phase 3 study, B-VEC significantly improved wound healing at 3 and 6 months compared to placebo, and in a US open-label extension (OLE) study, weekly B-VEC administration was well tolerated for up to 112 weeks. The present study was conducted to confirm the efficacy and safety of B-VEC in a cohort of Japanese DEB patients receiving weekly B-VEC treatment (4.0 × 109 plaque forming units (PFU)/mL) for 52 weeks. Wound healing assessments were conducted on a Primary Wound at visits corresponding to Month 3 (the secondary efficacy endpoint), Month 6 (the primary efficacy endpoint), and Months 9 and 12 (exploratory durability endpoints). Patient-reported outcome (PRO) measures were employed as exploratory analyses of efficacy. Safety was assessed by adverse events (AEs) and clinical laboratory tests. Five subjects enrolled in the study; one discontinued due to challenges with following wound dressing disposal guidelines. The study met its primary and secondary efficacy endpoints with 100% of Primary Wounds demonstrating complete closure at Months 6 and 3, respectively; durable complete closure was observed in 3/4 (75%) of wounds at Months 9 and 12. PROs indicated decreased pain, improvement in skin-specific quality of life, and moderate to high treatment satisfaction. Four subjects reported ten AEs; all were assessed as mild or moderate in severity and unrelated to treatment by Investigators. None were serious, severe, or led to treatment/study discontinuation. The results of the Japan OLE study are in agreement with the US Phase 3 and OLE studies, demonstrating the efficacy and safety of B-VEC in Japanese patients with DEB.
Trial Registration: Japan Registry of Clinical Trials: jRCT2053230075
期刊介绍：
The Journal of Dermatology is the official peer-reviewed publication of the Japanese Dermatological Association and the Asian Dermatological Association. The journal aims to provide a forum for the exchange of information about new and significant research in dermatology and to promote the discipline of dermatology in Japan and throughout the world. Research articles are supplemented by reviews, theoretical articles, special features, commentaries, book reviews and proceedings of workshops and conferences.
Preliminary or short reports and letters to the editor of two printed pages or less will be published as soon as possible. Papers in all fields of dermatology will be considered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
